Association between primary Sjogren’s syndrome, arterial stiffness, and subclinical atherosclerosis: a systematic review and meta-analysis
In rheumatoid arthritis and systemic lupus erythematosus, cardiovascular disease is frequently one of the leading causes of mortality or morbidity. Studies have shown that acute systemic inflammation and chronic systemic vasculitis are associated with endothelial dysfunction and atherosclerotic plaque formation, subsequently leading to cardiovascular disease. This meta-analysis aimed to explore the association of subclinical atherosclerosis and arterial stiffness in primary Sjogren’s syndrome. A comprehensive search of the MEDLINE and Embase databases was performed from date of inception through August 2017. The inclusion criterion was observational studies evaluating the association between primary Sjogren’s syndrome, subclinical atherosclerosis, and arterial stiffness by measuring pulse wave velocity (PWV) and intima–media thickness (IMT). Definitions of PSS and methods to assess PWV and IMT were recorded for each study. Different locations of IMT were evaluated including common carotid, internal carotid, and femoral arteries. The pooled mean difference (MD) of PWV and IMT and 95% confidence interval (CI) were calculated using a random-effect meta-analysis. The between-study heterogeneity of effect size was quantified using the Q statistic and I2. Data were extracted from eight observational studies involving 767 subjects. Pooled result demonstrated a significant increase in PWV in patients who have PSS compared with controls (MD = 1.30 m/s; 95% CI 0.48–2.12; p value = 0.002; I2 = 85%). Patients with PSS also have higher IMT (MD = 0.08 mm; 95% CI 0.04–0.11; p value < 0.01; I2 = 72%). Our study suggests that PSS is associated with arterial stiffness and subclinical atherosclerosis. Further studies need to be conducted to find the correlation of subclinical atherosclerosis in PSS with the cardiovascular event, the pathophysiological changes of arterial stiffness in PSS, and the benefit of statins, because controlling cardiovascular risk factors or disease activity could potentially help avoid progression of atherosclerosis to overt cardiovascular disease.
KeywordsArterial stiffness Atherosclerosis Cardiovascular disease Sjogren’s syndrome
Compliance with ethical standards
This article does not contain any studies with human participants or animals performed by any of the authors.
- 5.Shiboski SC, Shiboski CH, Criswell L, Baer A, Challacombe S, Lanfranchi H et al (2012) American College of Rheumatology classification criteria for Sjogren's syndrome: a data-driven, expert consensus approach in the Sjogren's International Collaborative Clinical Alliance cohort. Arthritis Care Res (Hoboken) 64(4):475–487CrossRefGoogle Scholar
- 10.Higgins JPT, Green S (eds) (2011) Cochrane handbook for systematic reviews of interventions version 5.1.0 [updated March 2011]. The Cochrane Collaboration. Available from http://handbook.cochrane.org
- 14.Atzeni F, Sarzi-Puttini P, Signorello MC, Gianturco L, Stella D, Boccassini L et al (2014) New parameters for identifying subclinical atherosclerosis in patients with primary Sjogren's syndrome: a pilot study. Clin Exp Rheumatol 32(3):361–368Google Scholar
- 15.Gravani F, Papadaki I, Antypa E, Nezos A, Masselou K, Ioakeimidis D, Koutsilieris M, Moutsopoulos HM, Mavragani CP (2015) Subclinical atherosclerosis and impaired bone health in patients with primary Sjogren's syndrome: prevalence, clinical and laboratory associations. Arthritis Res Ther 17(1):99CrossRefGoogle Scholar
- 18.Zardi EM, Basta F, Afeltra A (2016) Levels of vitamin D, disease activity and subclinical atherosclerosis in post-menopausal women with Sjogren's syndrome: does a link exist? In Vivo 30(5):721–725Google Scholar
- 21.Valim V, Gerdts E, Jonsson R, Ferreira GA, Brokstad KA, Brun JG et al (2016) Atherosclerosis in Sjogren's syndrome: evidence, possible mechanisms and knowledge gaps. Clin Exp Rheumatol 34(1):133–142Google Scholar
- 29.Chiang CH, Liu CJ, Chen PJ, Leu HB, Hsu CY, Huang PH et al (2013) Primary Sjogren's syndrome and the risk of acute myocardial infarction: a nationwide study. Zhonghua Minguo Xin Zang Xue Hui Za Zhi 29(2):124–131Google Scholar
- 33.Bartoloni E, Baldini C, Schillaci G, Quartuccio L, Priori R, Carubbi F, Bini V, Alunno A, Bombardieri S, de Vita S, Valesini G, Giacomelli R, Gerli R (2015) Cardiovascular disease risk burden in primary Sjogren's syndrome: results of a population-based multicentre cohort study. J Intern Med 278(2):185–192CrossRefGoogle Scholar
- 35.Krasnokutsky S, Romero AG, Bang D, Pike VC, Shah B, Igel TF, Dektiarev I, Guo Y, Zhong J, Katz SD, Pillinger MH (2018) Impaired arterial responsiveness in untreated gout patients compared with healthy non-gout controls: association with serum urate and C-reactive protein. Clin Rheumatol 37(7):1903–1911CrossRefGoogle Scholar
- 36.Biesbroek PS, Heslinga SC, van de Ven PM, Peters MJL, Amier RP, Konings TC, Maroules CD, Ayers C, Joshi PH, van der Horst-Bruinsma IE, van Halm VP, van Rossum AC, Nurmohamed MT, Nijveldt R (2018) Assessment of aortic stiffness in patients with ankylosing spondylitis using cardiovascular magnetic resonance. In: Clin Rheumatol, vol 37, pp 2151–2159Google Scholar